Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection

Vancomycin is the drug of choice for treating <i>Clostridioides difficile</i> infection (CDI). We compare CDI resolution with vancomycin taper, pulse, and taper-and-pulse regimens. We searched for Medline, Embase, Cochrane, and Scopus through October 9^th, 2020. Taper regimen was defined as dose reduction over time; pulse was a regimen less frequent than daily. Studies assessing CDI resolution rates were included. Meta-analyses for resolution rates were performed using weighted proportion ratios (WPR). Ten studies with 675 patients treated with vancomycin regimens were included. Resolution rates were 83% (212/266, 95% CI 69–94%, <i>I² </i>= 85%) for taper-and-pulse, 68% (264/383, 95% CI 57–78%, <i>I² = </i>72%) for taper alone, and 54% (11/26 95% CI 0–100%, <i>I² = </i>86%) for pulse alone regimens. Taper-and-pulse was superior to taper alone (WPR 83% vs 68%, p Limitations of our analysis are a small number of included studies and heterogeneity. Vancomycin taper-and-pulse seems superior to pulse alone or taper alone for recurrent CDI. A randomized controlled trial comparing vancomycin taper-and-pulse to fidaxomicin and microbiome restoration is needed.